Why is P & G Health Ltd falling/rising?

As of 18-Aug, Procter & Gamble Health Ltd is experiencing a decline in its stock price, currently at Rs 6,212.90, which reflects a decrease of Rs 73.4 or 1.17%. The stock has underperformed its sector today by 1.4%, and while it is close to its 52-week high, it remains 4.46% away from that peak. Over the past week, the stock has seen a decline of 1.54%, but it has performed well over the longer term, with a year-to-date increase of 18.79% and a one-year return of 20.53%. Despite these positive long-term returns, there are concerns regarding falling investor participation, as evidenced by a significant drop in delivery volume, which has decreased by 47.32% against the five-day average. Additionally, while the company boasts high management efficiency and strong institutional holdings, its long-term growth prospects appear limited, with net sales growing at only 7.39% annually over the last five years.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has gained 0.83% over the past week. This underperformance relative to the market may contribute to investor sentiment affecting the stock negatively. Although the company has demonstrated strong financial results and a high return on equity, its valuation appears expensive with a price-to-book ratio of 19.2, which could deter potential investors. The combination of high institutional ownership and market-beating performance over the past year suggests that there is confidence in the company's fundamentals; however, the current price movement indicates that short-term pressures and concerns about growth may be influencing the stock's decline.